Our findings reveal an unexpected role of AXL in resistance to TKI in CML cells, identify the molecular mechanisms involved in its overexpression and support the notion that AXL is a new marker of resistance to TKI in CML. This evidence concerns the gene AXL and chronic myelogenous leukemia, BCR-ABL1 positive.